Summary
On March 17, 2026, Robert Chess, a director at Twist Bioscience Corp (NASDAQ:TWST), sold 10,000 shares of the company’s common stock for total proceeds of $470,000. The shares were disposed of at $47 per share, a figure that the report notes was above the contemporaneous quoted stock price of $44.89. That disposal followed a six-month period during which Twist shares rose by roughly 59%.
Details of the transactions
In addition to the sale, Chess exercised stock options on the same date to purchase 10,000 shares at an exercise price of $11.89 per share. The exercise carried a notional cost of $118,900. Collectively, these moves altered Chess’s immediate holdings: he now directly holds 21,084 shares of Twist Bioscience common stock, and he maintains indirect ownership of 42,528 shares through the Chess 1997 Trust.
According to the filing, both the sale and the option exercise were completed pursuant to a pre-arranged Rule 10b5-1 trading plan that Chess adopted on December 10, 2025.
Company financial and strategic developments
Twist Bioscience reported results for the first quarter of fiscal 2026 that showed revenue of $103.7 million, a figure that topped analyst expectations by 2.96%. The company’s earnings per share, however, missed projections, with reported EPS of -$0.50 versus an anticipated -$0.43.
Separately, Twist entered into a licensing agreement with Invenra Inc. covering the B-Body bispecific antibody platform. Under the terms disclosed, Twist becomes a co-exclusive provider of that technology, a move the company said will broaden its antibody discovery services.
Governance and shareholder actions
At the 2026 Annual Meeting, shareholders voted to approve director elections and executive compensation. The company reported that holders representing approximately 91.81% of outstanding shares participated in the vote.
Context and note
The filings and company disclosures provide the transactional details and the corporate updates summarized above. No additional causes, motivations, or prospective outcomes are offered in the disclosures themselves.
Reported figures and dates are drawn from company filings and disclosures referenced in the report.